Skip to search formSkip to main contentSkip to account menu

Mitolactol

Known as: 6-dibromodideoxydulcitol, 6-dibromodulcitol, Dibromdicil 
A synthetic derivative of hexitol with antineoplastic and radiosensitizing properties. Mitolactol alkylates DNA via actual or derived epoxide groups… 
National Institutes of Health

Related topics

Related topics

24 relations

Narrower (9)

1,2-anhydro-6-bromogalactitolADM protocolBVMM protocolDMV protocol

Broader (1)

Antineoplastic Agents, Alkylating
DAVTH protocolIn BloodNCIt Antineoplastic Agent Terminologyagonists

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Increased Risk of Severe Recurrence of Hepatitis C Virus in Liver Transplant Recipients of Donation After Cardiac Death Allografts
Background. In hepatitis C virus (HCV) recipients of donation after cardiac death (DCD) grafts, there is suggestion of lower… 
2011
2011
Optimization of a miniaturized DBD plasma chip for mercury detection in water samples
In this work, an optimization study was conducted to investigate the performance of a custom-designed miniaturized dielectric… 
Highly Cited
1989
Highly Cited
1989
Fluorogenic reagent for thiols: 4-(N,N-dimethylaminosulphonyl)-7-fluoro-2,1,3-benzoxadiazole.
4-(N,N-Dimethylaminosulphonyl)-7-fluoro-2,1,3-benzoxadiazole (DBD-F) was synthesised for use as a more reactive, thiol-specific… 
Review
1988
Review
1988
Single-agent chemotherapy for advanced adenocarcinoma of the lung
SummarySystemic therapy with cytostatic agents has been widely used in the management of inoperable adenocarcinoma of the lung… 
1978
1978
Positive phase II trial of dibromodulcitol in patients with metastatic melanoma refractory to DTIC and a nitrosourea.
Twenty-five patients with measurable metastatic melanoma refractory to DTIC and a nitrosourea were treated with dibromodulcitol… 
1977
1977
Evaluation of adriamycin and dibromodulcitol in metastatic breast carcinoma.
A phase 1 to 2 evaluation of a combination of adriamycin (ADR) and dibromodulcitol (DBD) was performed in patients with… 
1976
1976
Phase I study of a five-day intermittent schedule for 1,2:5,6-dianhydrogalactitol (NSC-132313).
Because 1,2:5,6-dianhydrogalactitol (NSC-132313 (DAG; the main conversion reaction product of the treatment of dibromodulcitol by… 
1975
1975
A Phase III Study in Lung Carcinoma Comparing Hexamethylmelamine (NSC 13875) to Dibromodulcitol (NSC 104800)
A phase III study was designed comparing the effectiveness of Hexamethylmelamine (NSC 13875) to Dibromodulcitol (NSC 104800) in… 
1971
1971
Phase I study of dibromodulcitol (NSC-104800).
1969
1969
Clinical and pharmacologic experience with dibromodulcitol (NSC-104800). A new antitumor agent.